“Treatment in Immunotherapy and Chemotherapy”
The epidermal growth factor receptor inhibitors market is witnessing significant growth driven by advancements in targeted cancer therapies. These inhibitors, used primarily in treating non-small cell lung cancer and other solid tumors, block EGFR to prevent cancer cell growth. Innovation in next-generation EGFR inhibitors aims to overcome resistance to existing treatments, enhancing efficacy and patient outcomes. One notable trend is the shift towards combination therapies, where EGFR inhibitors are used alongside other treatments such as immunotherapy and chemotherapy to improve response rates and reduce relapse. The increasing focus on personalized medicine, with the help of advanced diagnostics and biomarker testing, is also fueling market expansion. As new treatments emerge, the market is expected to continue evolving with a stronger focus on precision-based therapies.
